BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 29363047)

  • 1. New perspectives on the definition and management of polycystic ovary syndrome.
    Pasquali R; Gambineri A
    J Endocrinol Invest; 2018 Oct; 41(10):1123-1135. PubMed ID: 29363047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
    Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
    Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
    Spritzer PM; Motta AB
    Int J Clin Pract; 2015 Nov; 69(11):1236-46. PubMed ID: 26289303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and challenges of polycystic ovary syndrome in adolescence.
    Agapova SE; Cameo T; Sopher AB; Oberfield SE
    Semin Reprod Med; 2014 May; 32(3):194-201. PubMed ID: 24715514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Female Pelvic Conditions: Polycystic Ovary Syndrome.
    Wilkinson LD; Brady PH; Gin GT; Rosenblum E
    FP Essent; 2022 Apr; 515():26-31. PubMed ID: 35420404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
    Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
    Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild androgen phenotypes.
    Carmina E
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):207-20. PubMed ID: 16772152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome and acne.
    Chuan SS; Chang RJ
    Skin Therapy Lett; 2010; 15(10):1-4. PubMed ID: 21076799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
    JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria.
    Mueller A; Dittrich R; Binder H; Hoffmann I; Beckmann MW; Cupisti S
    Eur J Med Res; 2006 Dec; 11(12):540-4. PubMed ID: 17182367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
    Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the treatment of polycystic ovary syndrome.
    Yildiz BO
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1295-305. PubMed ID: 15461558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatology of androgen-related disorders.
    Essah PA; Wickham EP; Nunley JR; Nestler JE
    Clin Dermatol; 2006; 24(4):289-98. PubMed ID: 16828411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of polycystic ovary syndrome: a practical guide.
    Stankiewicz M; Norman R
    Drugs; 2006; 66(7):903-12. PubMed ID: 16740005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Syndrome: Polycystic Ovary Syndrome.
    Mortada R; Williams T
    FP Essent; 2015 Aug; 435():30-42. PubMed ID: 26280343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best methods for identification and treatment of PCOS.
    Artini PG; Di Berardino OM; Simi G; Papini F; Ruggiero M; Monteleone P; Cela V
    Minerva Ginecol; 2010 Feb; 62(1):33-48. PubMed ID: 20186113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
    J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.